Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61

1.

Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.

Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C.

Value Health. 2013 Mar-Apr;16(2):288-96. doi: 10.1016/j.jval.2012.11.001. Epub 2013 Jan 23.

PMID:
23538180
[PubMed - indexed for MEDLINE]
3.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

PMID:
17346499
[PubMed - indexed for MEDLINE]
Free Article
4.

Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Greenhalgh J, Bagust A, Boland A, Fleeman N, McLeod C, Dundar Y, Proudlove C, Shaw R.

Health Technol Assess. 2009 Oct;13 Suppl 3:49-54. doi: 10.3310/hta13suppl3/08. Review.

PMID:
19846029
[PubMed - indexed for MEDLINE]
Free Article
5.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

PMID:
16545208
[PubMed - indexed for MEDLINE]
Free Article
6.

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

García-Foncillas J, Díaz-Rubio E.

Clin Transl Oncol. 2010 Aug;12(8):533-42. doi: 10.1007/s12094-010-0551-3. Review.

PMID:
20709651
[PubMed - indexed for MEDLINE]
7.

The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.

Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A.

Health Technol Assess. 2008 May;12(15):iii-ix, xi-162. Review.

PMID:
18462574
[PubMed - indexed for MEDLINE]
Free Article
8.

Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.

Frank M, Mittendorf T.

Pharmacoeconomics. 2013 Mar;31(3):215-28. doi: 10.1007/s40273-012-0017-2. Review.

PMID:
23338963
[PubMed - indexed for MEDLINE]
9.

Chemotherapy of metastatic colorectal cancer.

[No authors listed]

Prescrire Int. 2010 Oct;19(109):219-24. Review.

PMID:
21180382
[PubMed - indexed for MEDLINE]
10.

Panitumumab: a review of its use in metastatic colorectal cancer.

Keating GM.

Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000. Review.

PMID:
20481659
[PubMed - indexed for MEDLINE]
11.

The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.

Tappenden P, Jones R, Paisley S, Carroll C.

Eur J Cancer. 2007 Nov;43(17):2487-94. Epub 2007 Oct 1. Review.

PMID:
17910914
[PubMed - indexed for MEDLINE]
12.

The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.

Eng C.

Oncologist. 2010;15(1):73-84. doi: 10.1634/theoncologist.2009-0167. Epub 2010 Jan 12. Review.

PMID:
20067946
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Cetuximab in metastatic colorectal cancer.

Broadbridge VT, Karapetis CS, Price TJ.

Expert Rev Anticancer Ther. 2012 May;12(5):555-65. doi: 10.1586/era.12.25. Review.

PMID:
22594891
[PubMed - indexed for MEDLINE]
14.

Panitumumab: in metastatic colorectal cancer with wild-type KRAS.

Weber J, McCormack PL.

BioDrugs. 2008;22(6):403-11. doi: 10.2165/0063030-200822060-00006. Review.

PMID:
18998757
[PubMed - indexed for MEDLINE]
15.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

PMID:
16904047
[PubMed - indexed for MEDLINE]
Free Article
16.

Cetuximab in the treatment of patients with colorectal cancer.

Garrett CR, Eng C.

Expert Opin Biol Ther. 2011 Jul;11(7):937-49. doi: 10.1517/14712598.2011.582464. Epub 2011 May 11. Review.

PMID:
21557708
[PubMed - indexed for MEDLINE]
17.

Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.

Jean GW, Shah SR.

Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742. Review.

PMID:
18503402
[PubMed - indexed for MEDLINE]
18.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

PMID:
17999840
[PubMed - indexed for MEDLINE]
Free Article
19.

Spotlight on panitumumab in metastatic colorectal cancer.

Keating GM.

BioDrugs. 2010 Aug 1;24(4):275-8. doi: 10.2165/11205460-000000000-00000. Review.

PMID:
20623992
[PubMed - indexed for MEDLINE]
20.

Cetuximab for the first-line treatment of metastatic colorectal cancer.

Meads C, Round J, Tubeuf S, Moore D, Pennant M, Bayliss S.

Health Technol Assess. 2010 May;14 Suppl 1:1-8. doi: 10.3310/hta14Suppl1/01. Review.

PMID:
20507797
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk